Multidisciplinary Treatment and Research of Pancreatic Cancer

10:10 - 10:30, Room 104 (104講堂)

Department of Surgery
National Taiwan University Hospital

Speaker

Professor

Yu-Wen Tien
MD, PhD

田郁文 教授

Chang Gung Memorial Hospital
Linkou Medical Center

Moderator

Professor

Min-Fu Chen

MD, PhD, FACS

陳敏夫 教授

Abstract - 

Multidisciplinary treatment and research of pancreatic cancer

     Pancreatic ductal adenocarcinoma (PDAC) is the third (at presence) and will be the second (in 2030) leading cancer death in western countries with only an unsatisfying improvement in 5-year survival rates during last decades, from 4% in 1999 to 8.5% in 2018 when considering all stages. Reasons for poor outlook of pancreatic cancer include diagnosis at late stage and refractory to chemotherapy-, radiotherapy, targeted therapy, and immunotherapy. At presence, operation remains to be the only potentially curative treatment modality for PDAC. However, after a potential curative resection, more than 70% of patients have recurrences. The high prevalence of residual disease after potential curative resection justify systemic therapy. Many prospective randomized trials reported better survivals for patients with adjuvant therapy after resection of their PDAC. Besides, there are more and more recent reports of conversion operation after down-staging unresectable or even metastatic PDAC by systemic therapy. Multidisciplinary approach will be the most promising treatment for pancreatic cancer.

台大醫院消化外科國際論壇暨林天祐學術研討會

NTUH International Forum of Digestive Surgery & TY Lin Symposium

2020 台大醫院一般外科忘年會

2020 NTUH General Surgery Celebration Event

Multidisciplinary approach in pancreatic cancer

What

2020一般外科國際論壇暨林天祐學術研討會

When

January 18th, 2020

Where

​台大醫學院 104 講堂

Contact Us

To learn more, don’t hesitate to get in touch

  • White Facebook Icon
  • White Instagram Icon
  • White Twitter Icon
  • White LinkedIn Icon

© 2023 by TIC. Proudly created with Wix.com